AngioDynamics, Inc. (ANGO)
USD 8.93
(-3.56%)
USD 8.93
(-3.56%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 5.91 Million USD | -88.13% |
| 2023 | 49.81 Million USD | 47.46% |
| 2022 | 33.78 Million USD | 68.92% |
| 2021 | 20 Million USD | -51.02% |
| 2020 | 40.83 Million USD | -70.09% |
| 2019 | 136.54 Million USD | 45.69% |
| 2018 | 93.72 Million USD | -11.54% |
| 2017 | 105.94 Million USD | -21.13% |
| 2016 | 134.32 Million USD | -9.01% |
| 2015 | 147.62 Million USD | -7.15% |
| 2014 | 159 Million USD | 4.81% |
| 2013 | 151.7 Million USD | 1.14% |
| 2012 | 150 Million USD | 2190.08% |
| 2011 | 6.55 Million USD | -3.82% |
| 2010 | 6.81 Million USD | -3.75% |
| 2009 | 7.07 Million USD | -58.66% |
| 2008 | 17.11 Million USD | -1.81% |
| 2007 | 17.43 Million USD | 493.87% |
| 2006 | 2.93 Million USD | -5.32% |
| 2005 | 3.1 Million USD | -50.44% |
| 2004 | 6.25 Million USD | -67.99% |
| 2003 | 19.54 Million USD | 21.02% |
| 2002 | 16.14 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 4.72 Million USD | -90.51% |
| 2024 FY | 5.91 Million USD | -88.13% |
| 2024 Q3 | 3.96 Million USD | -6.0% |
| 2024 Q2 | 4.22 Million USD | -10.76% |
| 2024 Q4 | 5.91 Million USD | 49.08% |
| 2023 Q4 | 49.81 Million USD | -16.53% |
| 2023 Q3 | 59.68 Million USD | 19.86% |
| 2023 Q2 | 49.79 Million USD | -15.15% |
| 2023 Q1 | 58.69 Million USD | 73.73% |
| 2023 FY | 49.81 Million USD | 47.46% |
| 2022 Q1 | 25 Million USD | 25.0% |
| 2022 FY | 33.78 Million USD | 68.92% |
| 2022 Q2 | 25 Million USD | 0.0% |
| 2022 Q4 | 33.78 Million USD | 35.13% |
| 2022 Q3 | 25 Million USD | 0.0% |
| 2021 Q1 | 40 Million USD | -2.05% |
| 2021 Q4 | 20 Million USD | -33.33% |
| 2021 Q2 | 40 Million USD | 0.0% |
| 2021 Q3 | 30 Million USD | -25.0% |
| 2021 FY | 20 Million USD | -51.02% |
| 2020 FY | 40.83 Million USD | -70.09% |
| 2020 Q2 | 889 Thousand USD | 1.25% |
| 2020 Q3 | 15.23 Million USD | 1613.16% |
| 2020 Q4 | 40.83 Million USD | 168.13% |
| 2020 Q1 | 878 Thousand USD | -99.36% |
| 2019 Q2 | 148.27 Million USD | 57.04% |
| 2019 Q1 | 94.41 Million USD | 0.74% |
| 2019 FY | 136.54 Million USD | 45.69% |
| 2019 Q3 | 139.76 Million USD | -5.74% |
| 2019 Q4 | 136.54 Million USD | -2.3% |
| 2018 FY | 93.72 Million USD | -11.54% |
| 2018 Q1 | 104.78 Million USD | -1.09% |
| 2018 Q2 | 96.03 Million USD | -8.35% |
| 2018 Q3 | 94.87 Million USD | -1.2% |
| 2018 Q4 | 93.72 Million USD | -1.22% |
| 2017 Q3 | 107.05 Million USD | -14.09% |
| 2017 FY | 105.94 Million USD | -21.13% |
| 2017 Q4 | 105.94 Million USD | -1.03% |
| 2017 Q2 | 124.6 Million USD | -5.03% |
| 2017 Q1 | 131.2 Million USD | -2.33% |
| 2016 Q3 | 139.06 Million USD | -3.22% |
| 2016 Q4 | 134.32 Million USD | -3.4% |
| 2016 Q1 | 146.39 Million USD | -0.84% |
| 2016 FY | 134.32 Million USD | -9.01% |
| 2016 Q2 | 143.68 Million USD | -1.85% |
| 2015 FY | 147.62 Million USD | -7.15% |
| 2015 Q4 | 147.62 Million USD | -7.02% |
| 2015 Q3 | 158.77 Million USD | -3.74% |
| 2015 Q2 | 164.95 Million USD | 8.2% |
| 2015 Q1 | 152.45 Million USD | -4.12% |
| 2014 Q2 | 152.38 Million USD | -1.82% |
| 2014 FY | 159 Million USD | 4.81% |
| 2014 Q3 | 151.05 Million USD | -0.87% |
| 2014 Q4 | 159 Million USD | 5.26% |
| 2014 Q1 | 155.2 Million USD | 2.31% |
| 2013 FY | 151.7 Million USD | 1.14% |
| 2013 Q4 | 151.7 Million USD | -1.17% |
| 2013 Q2 | 154.3 Million USD | 3.14% |
| 2013 Q1 | 149.6 Million USD | -0.26% |
| 2013 Q3 | 153.49 Million USD | -0.52% |
| 2012 Q1 | 6.48 Million USD | -0.99% |
| 2012 Q2 | 6.41 Million USD | -1.08% |
| 2012 Q3 | 6.34 Million USD | -1.09% |
| 2012 Q4 | 150 Million USD | 2264.07% |
| 2012 FY | 150 Million USD | 2190.08% |
| 2011 Q3 | 6.61 Million USD | -0.97% |
| 2011 Q1 | 6.74 Million USD | -0.95% |
| 2011 FY | 6.55 Million USD | -3.82% |
| 2011 Q4 | 6.55 Million USD | -0.98% |
| 2011 Q2 | 6.68 Million USD | -0.96% |
| 2010 Q3 | 6.87 Million USD | -0.87% |
| 2010 Q4 | 6.81 Million USD | -0.87% |
| 2010 FY | 6.81 Million USD | -3.75% |
| 2010 Q2 | 6.93 Million USD | -0.86% |
| 2010 Q1 | 6.99 Million USD | -1.2% |
| 2009 Q3 | 7.16 Million USD | -1.17% |
| 2009 Q4 | 7.07 Million USD | -1.19% |
| 2009 FY | 7.07 Million USD | -58.66% |
| 2009 Q2 | 7.24 Million USD | -1.16% |
| 2009 Q1 | 7.33 Million USD | -57.17% |
| 2008 Q2 | 17.28 Million USD | -0.43% |
| 2008 Q4 | 17.11 Million USD | -0.49% |
| 2008 Q3 | 17.2 Million USD | -0.49% |
| 2008 FY | 17.11 Million USD | -1.81% |
| 2008 Q1 | 17.36 Million USD | -0.4% |
| 2007 Q1 | 2.89 Million USD | -1.53% |
| 2007 Q4 | 17.43 Million USD | -0.4% |
| 2007 Q3 | 17.5 Million USD | 515.11% |
| 2007 Q2 | 2.84 Million USD | -1.56% |
| 2007 FY | 17.43 Million USD | 493.87% |
| 2006 Q4 | 2.93 Million USD | -1.51% |
| 2006 Q2 | 3.02 Million USD | -1.44% |
| 2006 Q1 | 3.06 Million USD | -1.16% |
| 2006 FY | 2.93 Million USD | -5.32% |
| 2006 Q3 | 2.98 Million USD | -1.32% |
| 2005 Q3 | 3.14 Million USD | -1.26% |
| 2005 Q1 | 3.22 Million USD | -48.52% |
| 2005 Q2 | 3.18 Million USD | -1.24% |
| 2005 FY | 3.1 Million USD | -50.44% |
| 2005 Q4 | 3.1 Million USD | -1.27% |
| 2004 Q4 | 6.25 Million USD | -67.82% |
| 2004 Q3 | 19.43 Million USD | 0.0% |
| 2004 FY | 6.25 Million USD | -67.99% |
| 2003 FY | 19.54 Million USD | 21.02% |
| 2003 Q4 | 19.54 Million USD | 0.0% |
| 2002 FY | 16.14 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 85.7 Million USD | 93.1% |
| AtriCure, Inc. | 74.49 Million USD | 92.061% |
| Avinger, Inc. | 15.39 Million USD | 61.585% |
| Azenta, Inc. | 60.43 Million USD | 90.214% |
| BioLife Solutions, Inc. | 42.69 Million USD | 86.147% |
| The Cooper Companies, Inc. | 2.56 Billion USD | 99.77% |
| Daxor Corporation | 755.65 Thousand USD | -682.628% |
| Ekso Bionics Holdings, Inc. | 7.16 Million USD | 17.494% |
| Femasys Inc. | 6.7 Million USD | 11.743% |
| GlucoTrack, Inc. | 196 Thousand USD | -2917.347% |
| Harvard Bioscience, Inc. | 42.77 Million USD | 86.174% |
| Hologic, Inc. | 2.53 Billion USD | 99.767% |
| ICU Medical, Inc. | 1.7 Billion USD | 99.653% |
| Intuitive Surgical, Inc. | 89.8 Million USD | 93.414% |
| KORU Medical Systems, Inc. | 4.44 Million USD | -33.045% |
| LeMaitre Vascular, Inc. | 19.09 Million USD | 69.029% |
| Innovative Eyewear, Inc. | - USD | -Infinity% |
| Innovative Eyewear, Inc. | - USD | -Infinity% |
| Masimo Corporation | 970 Million USD | 99.39% |
| Microbot Medical Inc. | 231 Thousand USD | -2460.173% |
| Meihua International Medical Technologies Co., Ltd. | 7.33 Million USD | 19.33% |
| Merit Medical Systems, Inc. | 891.35 Million USD | 99.337% |
| Nephros, Inc. | 1.83 Million USD | -222.113% |
| NovoCure Limited | 596.24 Million USD | 99.008% |
| NEXGEL, Inc. | 2.79 Million USD | -111.365% |
| NEXGEL, Inc. | 2.79 Million USD | -111.365% |
| Singular Genomics Systems, Inc. | 75.28 Million USD | 92.145% |
| OraSure Technologies, Inc. | 13.5 Million USD | 56.206% |
| Pro-Dex, Inc. | 13.54 Million USD | 56.345% |
| Pulse Biosciences, Inc. | 9.14 Million USD | 35.324% |
| Predictive Oncology Inc. | 2.85 Million USD | -107.014% |
| Precision Optics Corporation, Inc. | 3.43 Million USD | -72.196% |
| QuidelOrtho Corporation | 2.61 Billion USD | 99.774% |
| Repligen Corporation | 711.8 Million USD | 99.169% |
| Sanara MedTech Inc. | 11.79 Million USD | 49.848% |
| STAAR Surgical Company | 35.83 Million USD | 83.496% |
| Sharps Technology, Inc. | - USD | -Infinity% |
| Utah Medical Products, Inc. | 342 Thousand USD | -1629.24% |
| DENTSPLY SIRONA Inc. | 2.29 Billion USD | 99.743% |
| Jin Medical International Ltd. | 4.11 Million USD | -43.788% |